Intra-Arterial Alteplase After Successful Thrombectomy for Acute Ischemic Stroke—Reply

In reply to the original report, it is stated that the primary outcome of the study was amended at month 12. The aim of this change was to improve clinical relevance and interpretability of the results. New randomized evidence and the established use of blinded mRS score assessment were taken into account. The amendment was implemented on February 10, 2025. At that time, 283 patients had been enrolled in the study. Of these, 214 patients had completed or were eligible for 90-day follow-up. Importantly, no interim analyses had been conducted at the time of the amendment. Also, no outcome data by treatment group were available, meaning the change was not informed by accumulating trial results.